Our findings suggest therapeutic activity of combined MEK/Bcl‐2 inhibitors in CLL and MM, and provide a mechanistic rationale for disease‐specific sensitivities to MEK/Bcl‐2 inhibition. Here, MAP2K7 is linked to B-cell chronic lymphocytic leukemia.